Literature DB >> 9988160

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

K Mupapa1, M Massamba, K Kibadi, K Kuvula, A Bwaka, M Kipasa, R Colebunders, J J Muyembe-Tamfum.   

Abstract

Between 6 and 22 June 1995, 8 patients in Kikwit, Democratic Republic of the Congo, who met the case definition used in Kikwit for Ebola (EBO) hemorrhagic fever, were transfused with blood donated by 5 convalescent patients. The donated blood contained IgG EBO antibodies but no EBO antigen. EBO antigens were detected in all the transfusion recipients just before transfusion. The 8 transfused patients had clinical symptoms similar to those of other EBO patients seen during the epidemic. All were seriously ill with severe asthenia, 4 presented with hemorrhagic manifestations, and 2 became comatose as their disease progressed. Only 1 transfused patient (12.5%) died; this number is significantly lower than the overall case fatality rate (80%) for the EBO epidemic in Kikwit and than the rates for other EBO epidemics. The reason for this low fatality rate remains to be explained. The transfused patients did receive better care than those in the initial phase of the epidemic. Plans should be made to prepare for a more thorough evaluation of passive immune therapy during a new EBO outbreak.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9988160     DOI: 10.1086/514298

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  155 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Ebola control: effect of asymptomatic infection and acquired immunity.

Authors:  Steve E Bellan; Juliet R C Pulliam; Jonathan Dushoff; Lauren Ancel Meyers
Journal:  Lancet       Date:  2014-10-15       Impact factor: 79.321

Review 4.  Passive immunity in prevention and treatment of infectious diseases.

Authors:  M A Keller; E R Stiehm
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 5.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

6.  Apheresis for collection of Ebola convalescent plasma in Liberia.

Authors:  Jerry F Brown; Kathleen Rowe; Peter Zacharias; James van Hasselt; John M Dye; David A Wohl; William A Fischer; Coleen K Cunningham; Nathan M Thielman; David L Hoover
Journal:  J Clin Apher       Date:  2016-07-08       Impact factor: 2.821

Review 7.  Ebola Virus Disease: Focus on Children.

Authors:  Athena P Kourtis; Kristie Appelgren; Michelle S Chevalier; Anita McElroy
Journal:  Pediatr Infect Dis J       Date:  2015-08       Impact factor: 2.129

8.  Impact of Intravenous Fluid Therapy on Survival Among Patients With Ebola Virus Disease: An International Multisite Retrospective Cohort Study.

Authors:  Adam R Aluisio; Derrick Yam; Jillian L Peters; Daniel K Cho; Shiromi M Perera; Stephen B Kennedy; Moses Massaquoi; Foday Sahr; Michael A Smit; Tao Liu; Adam C Levine
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

Review 9.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

10.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.